<DOC>
	<DOCNO>NCT00669435</DOCNO>
	<brief_summary>Angiotensin II propose lipid metabolism regulator . It known adipocytes secrete variety protein , TNFÎ± , plasminogen activator inhibitor ( PAI ) -1 , leptin , resistin adiponectin ; protein wide range biological effect associate insulin resistance . Adipocytes also produce angiotensinogen angiotensin II local renin-angiotensin system ( RAS ) present adipose tissue . In overweight obese hypertensive normocholesterolemic patient treatment AT1-receptor blocker ( Losartan ) may better effect hepatic steatosis visceral fat deposition antihypertensive treatment calcium channel blocker ( amlodipine ) . Simvastatin add group . The aim study evaluate effect losartan simvastatin ultrasonographic qualitative quantitative parameter overweight obese hypertensive normocholesterolemic patient hepatic steatosis .</brief_summary>
	<brief_title>Losartan Simvastatin Hypertensive Obeses With Liver Steatosis</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Gender : 50 % Male 50 % female Age : 4080 year Race : Caucasian Overweight obese : respectively BMI2530 kg/m2 BMI &gt; 30 kg m2 Hypertensive : PA &gt; 140/90 mmHg Normocholesterolemic ( LDL &lt; 160 mg/dl HDL &gt; 35 mg/dl ) Liver steatosis antihypertensive treatment wash period 2 week abnormal heart rest function ( EF &lt; 55 % ) . valvular heart disease congenital heart disease heart failure prior myocardial infarction diabetes renal disease liver disease connective tissue disease pregnancy lactation serious adverse experience sensitivity study drug component contraindication approve label</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Liver steatosis</keyword>
</DOC>